1. Salvadori P A, Menichetti L, Petroni D. La radio farmacia PET. In: VolterraniD,
Erba P, Mariani G, editors, Fondamenti di Medicina Nucleare. Milano: Springer Italia; 2010. 155-157.
2. Balcari N, Del Guerra A. Interazione dei raggi γ di annichilazione il tessuto
biologico. In:Volterrani D, Erba P, Mariani G, editors, Fondamenti di Medicina Nucleare. Milano: Springer Italia; 2010. 256.
3. Joshi U, Raijmakers M, Riphagen I, Teule GJJ, van Lingen A, Hoekstra OS.
Attenuation-corrected vs non attenuation corrected 2-deoxy-2-[F-18]fluoro-D- glucose Positron Emission Tomography in Oncology, a systematic review. Mol Imag and Biol 2007; 9:99-105.
4. Salvadori P A, Menichetti L, Petroni D. La radio farmacia PET. In: VolterraniD,
Erba P, Mariani G, editors, Fondamenti di Medicina Nucleare. Milano: Springer Italia; 2010. 157-158.
5. Warburg O. The metabolism of tumors. Dickens F, trans London: Constable,
1930:129-169.
6. Sokoloff L. Modeling metabolic processes in the brain in vivo. Ann Neurol
1984. 15Suppl:S1-11.
7. European Journal of Nuclear Medicine and Molecular Imaging. Vol 13
Number 5.
8. Volterrani D, Erba P A, Boni R, Bigi E, Mariani G. Tecniche diagnostiche PET
Medicina Nucleare. Milano: Springer Italia; 2010. 770-771
9. Ozols RF, Recurrent Ovarian Cancer : Evidence-based treatment, JCO 2002;
5:1161-1163.
10. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer, Br j Obstet Gynaecol 1998; 105:493-499.
11. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab2003; 17:139-147
12. Trimbos JB, Bolis G. European guidelines of staging of ovarian cancer. Int J Gynecol Cancer. 2000; 10:8-11.
13. FIGO annual report, vol. 24, J Epidemiol Biostat 2001; VI :107-138.
14. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sjövall K, Timmerman D, Vandewalle J, Van Gramberen M, Tropé CG. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357:176-182.
15. Pisano C, Greggi S, Tambaro R, Losito S, Iodice F, Di Maio M, Ferrari E, Falanga M, Formato R, Iaffaioli VR, Pignata S. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Anticancer Res. 2005; 25:3501-3505,
16. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinumera: a meta-analysis. J Clin Oncol. 2002; 20:1248-1259.
17. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R. Serum half-life of CA125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol. 1995;58:42-47.
18. Lu HK, Patterson AP, Wang L. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Can Res. 2004; 10:3291-3300.
19. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol. 1995;16:349-356.
20. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S, Angioli R, Manci N, Scambia G, Dell'Anna T, Fossati R, Floriani I, Rossi RS, Grassi R, Favalli G, Raspagliesi F, Giannarelli D, Martella L, Mangioni C. Systematicaortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005; 97:560-566.
21. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332:629-634.
22. Rose P G, Nerenstone S, Brady M, Pearson DC, Olt G, Rubin SC, Moore D H. A phase III randomized study of interval secondary cytoreduction in patients
with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol. 2002; 21(Abstr 802).
23. Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM.Randomizedphase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006; 102:432–439.
24. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy in Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.J Natl Cancer Inst.2003; 95:105-112.
25. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA.Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med.2006;354:34-43.
26. Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, Bruzzone M, Conte PF. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol. 2000; 76:157-162.
Lancet Oncol. 2003; 4:277-283.
28. Fujiwara K, Markman M, Morgan M, Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecologic Oncology. 2005; 97:10–15.
29. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Maggioni A, Cosio S, Frassi E, LaPresa MT, Fuso L, Cristofani R. Relationship between time interval from primary surgery to the start of taxane-plusplatinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol. 2005; 23:751-758. 30. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang
C, Alberts D. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460-2465.
31. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, Long HJ. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stageIII ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:2849-2855.
32. Scarfone G, Merisio C, Garavaglia E, Richiardi G, Tateo S, D'Agostino S, Zanaboni F, Donadello N, Polverino G, Villa A, Bolis G. A phase III trial of consolidation versus NIHIL (NIL) for advanced epithelial ovarian cancer (AEOC) after complete remission (CR). Proc Am Soc Clin Oncol. 2002; 21(abstr 812).
33. Pignata S., Deplacido S, Scambia G, Divagno G., Naglieri E, Vernaglia Lombardi A, Biamonte R, Marinaccio M, Guida T, Manzione L. Topotecan vs nihil after response to carboplatin and paclitaxel in advanced ovarian cancer. Early results of the MITO-1 (Multicenter Italian Trials in Ovarian Cancer) study. Proc Am Soc Clin Oncol. 2003; 22(abstr 1791).
34. Pfisterer J, Lortholary A, Kimming R, Weber B. Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages Iib-IV. Interim results of a gynaecologic cancer intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO. Proc Am Soc Clin Oncol. 2003; 22:446.
35. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol. 1997; 8:963-968.
36. Thigpen T: Second-line therapy for ovarian carcinoma: General concepts. ASCO Educational Book, 1999 Spring:564-566.
37. Gore M. Treatment of relapsed epithelial ovarian cancer. In: Perry MC, editor. 37th Annual Meeting of the American Society of Clinical Oncology Education Book, Spring 2001. Alexandria, VA: American Society of Clinical Oncology:
38. Ovarian Epithelial Cancer: Treatment guidelines. National Cancer Institute 2002. 39. Parmar MK, Ledermann JA, Colombo N. Paclitaxel plus platinum-based
chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 21:2099-2106.
40. Gadducci A, Fuso L, Cosio S, Landoni F, Maggino T, Perotto S, Sartori E, Testa A, Galletto L, Zola P. Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer? A Retrospective Italian Multicentric Study. Int J Gynecol Cancer. 2009;19:367-374.
41. Ovarian cancer: screening, treatment, and follow-up. NIH Consens Statement 1994; 12:1–30.
42. Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group Study. Ann Oncol 1996; 7:361–364.
43. Practice Guidelines in Oncology, version 1.2002, National Comprehensive Cancer Network. http://www.nccn.com
44. Guidelines about Epithelial ovarian cancer,www.mdanderson.org 45. Minimum Clinical Recommendations, ESMO 2002.
46. De Rosa V, Mangoni di Stefano ML, Brunetti A, Caraco C, Graziano R, Gallo MS, Maffeo A. Computed tomography and second-looksurgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan. Eur J Gynaecol Oncol.1995;16:123-129.
48. Clarke-Pearson DL, Bandy LC, Dudzinski M, Heaston D, Creasman WT. Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission. Correlation with surgical-pathologic findings. JAMA 1986;255:627–630.
49. Reuter KL, Griffin T, Hunter RE. Comparison of abdominopelvic computed tomography results and findings at second-look laparotomy in ovarian carcinoma patients. Cancer 1989;63:1123–1128.
50. Kainz C, Prayer L, Gitsch G et al. The diagnostic value of magnetic resonance imaging for the detection of tumor recurrence in patients with carcinoma of the ovaries. J Am Coll Surg 1994;178:239–244.
51. Kubik-Huch RA, Dorffler W, von Schulthess GK. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761–767.
52. Garcia Velloso MJ, Boan Garcia JF, Villar Luque LM, Aramendia Beitia JM, Lopez Garcia G, Richter Echeverria JA. F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125. Rev Esp Med Nucl 2003;22:217–223.
53. Funt SA, Hricak H, Abu-Rustum N, Mazumdar M, Felderman H, Chi DS. Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 2004;182:393–398.
54. Forstner R, Hricak H, Powel CB, Azizi L, Frankel SB, Stern JL. Ovarian cancer recurrence: value of MR imaging. Radiology 1995;196:715–720.
with perfluorocarbon-enhanced MR imaging, in 111-CYT-103 immunoscintigraphy, and CT. Radiology 1995;195:391–400.
56. Semelka RC, Lawrence PH, Shoenut JP, Heywood M, Kroeker MA, Lotocki R. Primary ovarian cancer: prospective comparison of contrast enhanced CT and pre and post contrast, fat suppressed MR imaging, with histologic correlation. J Magn Reson Imaging 1993;3:99–106.
57. Outwater EK, Siegelman ES, Wilson KM, Mitchell DG. Benign and malignant gynecologic disease: clinical importance of fluid and peritoneal enhancement in the pelvis at MR imaging. Radiology 1996;200:483–488.
58. Low RN, Barone RM, Lacey C, Sigeti JS, Alzate GD, Sebrechts CP. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium- containing contrast agents compared with unenhanced MR imaging and CT. Radiology 1997;204:513–520.
59. Fehm T, Heller F, Kramer S, Jager W, Gebauer G. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res 2005; 25:1551–1554.
60. Liberati A, Longo G, Ballini L, De Palma R. FDG-PET in oncologia. Criteri per un uso appropriato. Dossier Agenzia Sanitaria Regionale dell’Emilia-Romagna. 2007 .http://asr.regione.emiliaromagna.it/wcm/asr/collana_dossier/doss157.htm. 61. Fenchel S, Grab D, Nuessle K, Kotzerke J, Rieber A, Kreienberg R, Brambs HJ,
Reske SN. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology. 2002;223:780-788.
62. Rieber A, Nüssle K, Stöhr I, Grab D, Fenchel S, Kreienberg R, Reske SN, Brambs HJ. Preoperative diagnosis of ovarian tumors with MR imaging:
comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol. 2001;177:123-129.
63. Woodward PJ, Hosseinzadeh K, Saenger JS. From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics. 2004;24:225-246.
64. Rieber A, Nüssle K, Stöhr I, Grab D, Fenchel S, Kreienberg R, Reske SN, Brambs HJ. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol. 2001;177:123-129.
65. Fenchel S, Grab D, Nuessle K, Kotzerke J, Rieber A, Kreienberg R, Brambs HJ, Reske SN. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology. 2002;223:780-788.
66. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol. 2000;174:1005-1008.
67. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK.Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol. 2002;100:788-795.
68. Castellucci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C, Messa C, Meriggiola MC, Pelusi G, Al-Nahhas A, Rubello D, Fazio F, Fanti S Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun. 2007;28:589-595.
69. Schroder W, Zimny M, Rudlowsky C, Bull U, Rath W. The role of 18F-fluoro deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int j Gynecol Cancer 1999;9:117-122.
70. Nishizawa S, Inubushi M, Okada H. Physiological 18F-FDGuptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging. 2005;32:549-556.
71. Ames J, Blodgett T, Meltzer C. 18F-FDG uptake in an ovary containing a hemorrhagic corpus luteal cyst: false-positive PET/CT in a patient with cervical carcinoma. AJR Am J Roentgenol. 2005;185:1057-1059.
72. Jain KA, Friedman DL, Pettinger TW, Alagappan R, Jeffrey RB Jr, Sommer FG. Adnexal masses: comparison of specificity of endovaginal US and pelvic MR imaging. Radiology. 1993;186:697-704.
73. Buy JN, Ghossain MA, Hugol D, Hassen K, Sciot C, Truc JB, Poitout P, Vadrot D. Characterization of adnexal masses: combination of color doppler and conventional sonography compared with spectral doppler analysis alone and conventional sonography alone. AJR Am J Roentgenol. 1996;166:385-393. 74. Kinkel K, Hricak H, Lu Y, Tsuda K, Filly RA. US characterization of ovarian
masses: a meta-analysis. Radiology. 2000;217:803-811.
75. Yoshida Y, Kurokawa T, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol. 2004;182:227-233.
76. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Fukasawa I, Inaba N, Sugimura K. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging
ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging. 2008;35:1912-1920.
77. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005; 23:7445-7453.
78. Nishiyama Y, Yamamoto Y, Kanenishi K, Ohno M, Hata T, Kushida Y, Haba R, Ohkawa M. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging. 2008;35:287- 295.
79. Sassen S, Schmalfeldt B,Avril N, Kuhn W, Busch R, Höfler H, Fend F, Nährig J. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer.Hum Pathol. 2007;38:926-934. 80. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-yearfollow-
up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999;93:21-24.
81. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol. 2001;82:17-21.
82. Cho SM, Ha HK, Byun JY, Lee JM, Kim CJ, Nam-Koong SE, Lee JM. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol. 2002;179:391-395.
83. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, Vigano R, Picchio M, Taccagni G, Maschio AD, Fazio F. Integrated FDGPET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology. 2004 Nov;233(2):433-40.
84. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol. 2002;85:53-58.
85. Gu P, Pan LL, Wu SQ, Sun L, Huang G: CA125, PET alone, PET-CT, CT and NRI in diagnosing recurrent ovarian carcinoma. A systematic review and meta- analysis. Eur j Radiol 2009; 71:164-174
86. Picchio M, Sironi S, Messa C, Mangili G, Landoni C, Gianolli L, Zangheri B, Viganò R, Aletti G, De Marzi P, De Cobelli F, Del Maschio A, Ferrari A, Fazio
F. Advanced ovarian carcinoma: usefulness of [18F]FDG-PET in combination
with CT for lesion detection after primary treatment. Q J Nucl Med. 2003;47:77- 84.
87. Nanni C, Rubello D, Farsad M, De Iaco P, Sansovini M, Erba P, Rampin L,
Mariani G, Fanti S. [18F]FDGPET/CT in the evaluation of recurrent ovarian
cancer: a prospective study on forty-one patients. Eur J Surg Oncol. 2005;31:792-797.
88. Tharll MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/TC) in recurrent ovarian cancer. Gynecol Oncol 2007; 105:17-22.
V, Crivellaro C, Messa C, Fazio F. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging. 2007;34:658-666.
90. Choi HJ, Roh JW, Seo SS, Lee S, Kim JY, Kim SK, Kang KW, Lee JS, Jeong JY, Park SY. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer. 2006; 106:914-922.